Completed PHASE1 INTERVENTIONAL NCT00004496

Phase I Study of Alpha-Melanocyte Stimulating Hormone in Patients With Acute Renal Failure

Sponsor: University of Texas

Interventions alpha-melanocyte stimulating hormone

Updated 5 times since 2017 Last updated: Mar 24, 2015 Started: Feb 28, 1999 Completion: Sep 30, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00004496, this PHASE1 trial focuses on Acute Renal Failure and remains completed. Sponsored by University of Texas, it has been updated 5 times since 1999, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Feb 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Texas

Data source: FDA Office of Orphan Products Development

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dallas, United States